In our study, we found that CMTM4 can modulate the tumor immune microenvironment by promoting EGFR recycling to increase G-CSF and CCL-1 production, which recruit neutrophils and MDSC to induce an immune suppressive tumor microenvironment. The gene discussed is CCL1; the disease is neoplasm.